FDA Widens Investigation Into AstraZeneca COVID-19 Vaccine

The transcript discusses the pause in AstraZeneca's COVID-19 vaccine trials after two participants fell ill. The FDA is reviewing data from earlier studies to check for similar side effects. An independent study suggests the side effects are unlikely linked to the vaccine. Trials have resumed in several countries, and AstraZeneca is working with the FDA to resume US trials. The CEO expects the vaccine to be ready by the end of the year.

What prompted the FDA to examine data from earlier studies in the AstraZeneca vaccine trial?

• Two participants fell ill during the trial.

• The vaccine was found to be ineffective.

• The trial was completed ahead of schedule.

• The vaccine was approved without sufficient data.

What was the rare condition diagnosed in a UK participant that led to the pause in AstraZeneca's trials?

• Kidney failure

• Spinal inflammatory disorder

• Heart disease

• Lung infection

According to an independent study, what was concluded about the side effects experienced by the participants?

• They were definitely caused by the vaccine.

• They were due to pre-existing conditions.

• They were caused by a different medication.

• They were unlikely to be associated with the vaccine.

In which countries have AstraZeneca's trials resumed?

• China, Russia, Australia, and New Zealand

• USA, Canada, Mexico, and Japan

• Germany, France, Italy, and Spain

• Britain, Brazil, India, and South Africa

What did AstraZeneca's CEO say about the COVID-19 vaccine's availability?

• It would be ready by the end of the year.

• It would be available in six months.

• It would be delayed until next year.

• It would be ready in two years.